# Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic Soft Tissue Sarcoma

> **NCT07291297** · PHASE2 · RECRUITING · sponsor: **Wake Forest University Health Sciences** · enrollment: 50 (estimated)

## Conditions studied

- Sarcoma Metastatic
- Sarcoma, Soft Tissue

## Interventions

- **DRUG:** Metformin Hydrochloride ER

## Key facts

- **NCT ID:** NCT07291297
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-04
- **Primary completion:** 2028-10
- **Final completion:** 2033-10
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-03-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07291297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07291297, "Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07291297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*